Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer is a research paper published in Frontiers in Oncology (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 1R01CA242917-01A1, 1R01CA281980-01, 1R01CA262028-01A1
NCI NIH HHS
Grant: R01 CA242917
National Institutes of Health
Grant: 1R01CA262028-01A1
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
National Institutes of Health
Grant: 1R01CA281980-01
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
National Institutes of Health
Grant: 1R01CA242917-01A1
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women
Fields of Study
Keywords